- The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion recommending approval of Novo Nordisk's (NVO -2.2%) Saxenda (liraglutide 3 mg) for the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity, in patients with an initial Body Mass Index (BMI) of >=30 kg/m2 (obese) or >=27 kg/m2 to <30 kg/m2 (overweight) who have at least one weight-related co-morbidity (e.g. hypertension, hypercholesterolemia, type 2 diabetes).
- A final decision by the European Commission usually takes ~60 days.
- The FDA approved Saxenda last month.
- Related tickers: (OREX +1.2%)(VVUS -4.6%)(ARNA -1.4%)